A case of reversible cerebral vasoconstriction syndrome associated with anti-phospholipid antibody syndrome and systemic lupus erythematosus.

• 发表时间: Sep 2021
• 来源期刊: eNeurologicalSci
• DOI: 10.1016/j.ensci.2021.100351
• PMID: 34258413
• 文章类型: Case Reports
• 作者列表: Shima A,Maki T,Mimura N,Yamashita H,Emoto N,Yoshifuji H,Takahashi R

关键词: Anti-phospholipid antibody syndrome; Cilostazol; Endothelin-1; Lomerizine; Reversible cerebral vasoconstriction syndrome

Abstract

The pathomechanisms and treatment strategy for rare presentations of reversible cerebral vasoconstriction syndrome (RCVS) with anti-phospholipid syndrome (APS) remain to be determined. We report a 67-year-old woman with APS who presented with ischemic stroke due to RCVS. She was treated with low-dose cilostazol and lomerizine hydrochloride, which resulted in functional improvement and recovery of vasoconstriction within 12 weeks. Her plasma endothelin-1 level was decreased after relief of vasoconstriction, compared with the pre-treatment condition. Increased plasma endothelin-1 may be related to the underlying pathomechanism of RCVS with APS, against which cilostazol and lomerizine hydrochloride could be effective.